Join
Live feed
·
PRReleasevia Quantisnow
Vivani Medical Inc. logo

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

ByQuantisnow·Wall Street's wire, on your screen.
VANI· Vivani Medical Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VANI (Vivani Medical Inc.) and more on Quantisnow.